Fairvalue-Calculator Fairvalue-Calculator
EN DE

ToolGen Incorporated (199800) Fair Value & Analysis

Healthcare · KR · Market cap 403B KRW

Price48,100 KRW
Fair Value27,941 KRW
Upside-41.9%
Quality95/100
Evidence: Low Range 20,956 KRW – 34,926 KRW

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

ToolGen Incorporated (199800) currently trades at 48,100 KRW, while our model-based Fair Value estimate is 27,941 KRW — implying the stock looks roughly 41.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

ToolGen Incorporated, a biotechnology company, focuses on the development of genome editing technology in South Korea. The company develops clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene scissors for gene editing in eukaryotic cells. It is involved in patent monetization, treatment, and seed businesses. ToolGen Incorporated was founded in 1999 and is based in Seoul, South Korea.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is ToolGen Incorporated (199800) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 27,941 KRW versus a price of 48,100 KRW — about −42% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 199800?
Our 21-model fair value for ToolGen Incorporated is 27,941 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 48,100 KRW.
What is the quality score of 199800?
ToolGen Incorporated has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.